Researchers have successfully 3D printed insulin-producing human pancreas cells that could revolutionize treatment for Type 1 ...

July kicks off the latter half of 2025, and the first six months of this year have been eventful, to say the least. Yet, the ...

After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $42.5 and $55.0 for CRISPR Therapeutics, spanning the last three ...

A recent study involving researchers from the University of Basel reveals that slowing down the intracellular transport of ...

Cellares grows in NJ and globally with Smart Factories and key partnerships to advance scalable, cost-effective cell therapy ...

Changing how biopharmas package their products, how regulators review new drugs and how mutated genes are fixed could make ...

Last month, a baby got the world’s first personalized gene-editing treatment. What will this mean for millions of others with ...

CRISPR Therapeutics (NASDAQ:CRSP) has delayed a much-anticipated Phase 1 trial readout for CTX320, its in vivo gene editing ...

When faced with the myriad diseases and equally numerous targets for potential drugs the company could pursue, Kewalramani ...

CRISPR Therapeutics CRSP and Intellia Therapeutics NTLA are leading developers of therapies that utilize the Nobel ...

In a step toward treating mitochondrial diseases, researchers in the Netherlands have successfully edited harmful mutations ...

Repositioning genes awakens fetal hemoglobin to treat disease. CRISPR editing may change future gene therapy. Researchers ...